×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
TAK – takeda pharmaceutical company limited american depositary shares (each representing 1/2 of a share of) (US:NYSE)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
TAK
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/14
10:25 pm
tak
Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now? [Yahoo! Finance]
Low
Report
Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now? [Yahoo! Finance]
4/14
04:59 am
tak
AI in Pharmacovigilance Course: Comprehensive Introduction to the Transformative Impact of Artificial Intelligence on Drug Safety and Monitoring (ONLINE EVENT: May 18, 2026) [Yahoo! Finance]
Low
Report
AI in Pharmacovigilance Course: Comprehensive Introduction to the Transformative Impact of Artificial Intelligence on Drug Safety and Monitoring (ONLINE EVENT: May 18, 2026) [Yahoo! Finance]
4/8
10:00 am
tak
Takeda Pharmaceutical (TAK) was upgraded by Sanford C. Bernstein from "market perform" to "outperform".
Low
Report
Takeda Pharmaceutical (TAK) was upgraded by Sanford C. Bernstein from "market perform" to "outperform".
4/3
02:10 pm
tak
Takeda (TAK) Receives FDA Priority Review for Rusfertide in PV Treatment [Yahoo! Finance]
Medium
Report
Takeda (TAK) Receives FDA Priority Review for Rusfertide in PV Treatment [Yahoo! Finance]
4/3
01:47 pm
tak
Major biopharmaceutical company to lay off nearly 250 workers in MA [Yahoo! Finance]
Medium
Report
Major biopharmaceutical company to lay off nearly 250 workers in MA [Yahoo! Finance]
4/1
01:47 pm
tak
DIA's LIFT Series Brings Startup Pitch Competitions, Innovation Programming to Global Annual Meeting [Yahoo! Finance]
Low
Report
DIA's LIFT Series Brings Startup Pitch Competitions, Innovation Programming to Global Annual Meeting [Yahoo! Finance]
3/30
01:06 pm
tak
Massachusetts' largest biopharma employer to lay off 237 in Cambridge [Yahoo! Finance]
Low
Report
Massachusetts' largest biopharma employer to lay off 237 in Cambridge [Yahoo! Finance]
3/30
02:16 am
tak
4BIO Capital strengthens investment leadership with appointment of Therese Liechtenstein as Partner and Tetsu Maruyama as Venture Partner [Yahoo! Finance]
Low
Report
4BIO Capital strengthens investment leadership with appointment of Therese Liechtenstein as Partner and Tetsu Maruyama as Venture Partner [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Symbol
Headline
Impact
4/6
06:20 am
tak
Form 3 TAKEDA PHARMACEUTICAL For: Apr 01 Filed by: Greenway Nicola Deidre Petal
Low
Report
Form 3 TAKEDA PHARMACEUTICAL For: Apr 01 Filed by: Greenway Nicola Deidre Petal
4/6
06:19 am
tak
Form 3 TAKEDA PHARMACEUTICAL For: Apr 01 Filed by: Farajallah Awny Samaan Botros
Low
Report
Form 3 TAKEDA PHARMACEUTICAL For: Apr 01 Filed by: Farajallah Awny Samaan Botros
4/6
06:17 am
tak
Form 3 TAKEDA PHARMACEUTICAL For: Apr 01 Filed by: Ibrahim Ramy Riad Ahmed
Low
Report
Form 3 TAKEDA PHARMACEUTICAL For: Apr 01 Filed by: Ibrahim Ramy Riad Ahmed
3/30
06:27 am
tak
Form 6-K TAKEDA PHARMACEUTICAL For: Mar 30
Low
Report
Form 6-K TAKEDA PHARMACEUTICAL For: Mar 30
3/26
06:04 am
tak
Form 6-K TAKEDA PHARMACEUTICAL For: Mar 26
Low
Report
Form 6-K TAKEDA PHARMACEUTICAL For: Mar 26
3/25
06:04 am
tak
Form 6-K TAKEDA PHARMACEUTICAL For: Mar 25
Low
Report
Form 6-K TAKEDA PHARMACEUTICAL For: Mar 25
3/18
06:20 am
tak
Form 3 TAKEDA PHARMACEUTICAL For: Mar 18 Filed by: Kim Julie So-Young
Low
Report
Form 3 TAKEDA PHARMACEUTICAL For: Mar 18 Filed by: Kim Julie So-Young
3/18
06:18 am
tak
Form 3 TAKEDA PHARMACEUTICAL For: Mar 18 Filed by: Furney Natalie Anne Marie
Low
Report
Form 3 TAKEDA PHARMACEUTICAL For: Mar 18 Filed by: Furney Natalie Anne Marie
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/2
Takeda Receives Positive CHMP Opinion for ALUNBRIG® (brigatinib) as a First-Line Treatment for ALK+ Non-Small Cell Lung Cancer
5.1%
4/6 European Commission Approves Takeda’s ALUNBRIG® (brigatinib) as a First-Line Treatment for ALK+ NSCLC 4.9%
7/31 Takeda Announces FY2019 Key Performance Indicators Aligned with Shareholder Value Creation and Focused on Successful Integration 4.9%
3/4 Takeda Completes Sale of Select OTC and Non-Core Assets to STADA 4.8%
4/10 Takeda Pharmaceutical Co Ltd (NYSE: TAK) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $18.00 price target on the stock. 4.1%
5/9 Asia Markets: Asian markets mostly gain despite looming U.S. tariff hikes targeting Chinese goods [MarketWatch] 4.1%
11/1 Takeda Pharmaceutical Co. Ltd (TKPHF) CEO Christophe Weber on Q3 2019 Results - Earnings Call Transcript [Seeking Alpha] 3.8%
4/27 Takeda ProThera Collaboration, And Other News: The Good, Bad And Ugly Of Biopharma [Seeking Alpha] 3.8%
2/4 Japan's Takeda forecasts surprise full-year operating profit [Yahoo! Finance News] 3.2%
5/17 Canadian Blood Services warns of imminent shortage of take-home immune globulin drug [Toronto Globe and Mail (Ontario, Canada)] 3.1%
4/6 European Commission Approves Takeda’s ALUNBRIG® (brigatinib) as a First-Line Treatment for ALK+ NSCLC 4.9%
7/31 Takeda Announces FY2019 Key Performance Indicators Aligned with Shareholder Value Creation and Focused on Successful Integration 4.9%
3/4 Takeda Completes Sale of Select OTC and Non-Core Assets to STADA 4.8%
4/10 Takeda Pharmaceutical Co Ltd (NYSE: TAK) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $18.00 price target on the stock. 4.1%
5/9 Asia Markets: Asian markets mostly gain despite looming U.S. tariff hikes targeting Chinese goods [MarketWatch] 4.1%
11/1 Takeda Pharmaceutical Co. Ltd (TKPHF) CEO Christophe Weber on Q3 2019 Results - Earnings Call Transcript [Seeking Alpha] 3.8%
4/27 Takeda ProThera Collaboration, And Other News: The Good, Bad And Ugly Of Biopharma [Seeking Alpha] 3.8%
2/4 Japan's Takeda forecasts surprise full-year operating profit [Yahoo! Finance News] 3.2%
5/17 Canadian Blood Services warns of imminent shortage of take-home immune globulin drug [Toronto Globe and Mail (Ontario, Canada)] 3.1%
TOP News Decliners
3/17
The Lancet publishes papers from two studies of Takeda’s dengue vaccine candidate
-10.1%
5/14 Takeda forecasts operating loss as Shire integration costs mount [FT.com - Mergermarket] -8.0%
2/26 Form POS AM TAKEDA PHARMACEUTICAL -6.6%
10/21 Retrospective Real-World Comparative Analysis Highlights Safety of Vedolizumab and Anti-TNFa Therapies in Biologic-Naïve Patients with Ulcerative Colitis or Crohn’s Disease -5.0%
11/9 2 Biotech Stocks Fighting Alzheimer’s Disease to Own Now [The Motley Fool] -4.0%
5/16 Takeda Pharmaceutical Co Ltd (NYSE: TAK) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -3.6%
11/8 New Analyses from the Phase 3 HELP Study™ Open-Label Extension in Hereditary Angioedema Evaluate Efficacy and Safety of TAKHZYRO® (lanadelumab-flyo) Injection During Extended Study Treatment Period -3.6%
7/9 Takeda Continues Ongoing Inclusion in the FTSE4Good Developed Index & MSCI ESG Leaders Index -3.0%
3/4 Japan's Takeda Pharma says it is developing coronavirus drug [Reuters (UK)] -2.7%
3/4 Japan stocks track Wall Street higher, but virus worries weigh [Reuters] -2.7%
5/14 Takeda forecasts operating loss as Shire integration costs mount [FT.com - Mergermarket] -8.0%
2/26 Form POS AM TAKEDA PHARMACEUTICAL -6.6%
10/21 Retrospective Real-World Comparative Analysis Highlights Safety of Vedolizumab and Anti-TNFa Therapies in Biologic-Naïve Patients with Ulcerative Colitis or Crohn’s Disease -5.0%
11/9 2 Biotech Stocks Fighting Alzheimer’s Disease to Own Now [The Motley Fool] -4.0%
5/16 Takeda Pharmaceutical Co Ltd (NYSE: TAK) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -3.6%
11/8 New Analyses from the Phase 3 HELP Study™ Open-Label Extension in Hereditary Angioedema Evaluate Efficacy and Safety of TAKHZYRO® (lanadelumab-flyo) Injection During Extended Study Treatment Period -3.6%
7/9 Takeda Continues Ongoing Inclusion in the FTSE4Good Developed Index & MSCI ESG Leaders Index -3.0%
3/4 Japan's Takeda Pharma says it is developing coronavirus drug [Reuters (UK)] -2.7%
3/4 Japan stocks track Wall Street higher, but virus worries weigh [Reuters] -2.7%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: